Selection of threose nucleic acid aptamers to block PD-1/PD-L1 interaction for cancer immunotherapy

被引：53
|
作者：
Li, Xintong [1 ,2 ,3 ]
Li, Zhe [1 ,4 ]
Yu, Hanyang [1 ,2 ,3 ]
机构：
[1] Nanjing Univ, Coll Engn & Appl Sci, Dept Biomed Engn, Jiangsu Key Lab Artificial Funct Mat, Nanjing 210023, Jiangsu, Peoples R China
[2] Nanjing Univ, State Key Lab Coordinat Chem, Nanjing 210023, Jiangsu, Peoples R China
[3] Nanjing Univ, Chem & Biomed Innovat Ctr ChemBIC, Nanjing 210023, Jiangsu, Peoples R China
[4] Nanjing Univ, State Key Lab Analyt Chem Life Sci, Nanjing 210023, Jiangsu, Peoples R China
来源：
CHEMICAL COMMUNICATIONS | 2020年 / 56卷 / 93期
基金：
中国国家自然科学基金;
关键词：
TNA; REPLICATION; EVOLUTION; SYSTEM; WORLD;
D O I：
10.1039/d0cc06032a
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
Threose nucleic acid (TNA) aptamers were selected in vitro to bind PD-L1 protein and inhibit its interaction with PD-1. These biologically stable TNA aptamers bound target proteins with nanomolar affinities, and effectively blocked PD-1/PD-L1 interaction in vitro. After injection into a colon cancer xenograft mouse model, the TNA aptamer N5 was specifically accumulated at the tumour site, and significantly inhibited tumour growth in vivo.
引用
收藏
页码：14653 / 14656
页数：4
相关论文
共 50 条
  • [1] Divergent Expression of PD-1 as Challenges and Chances of Immunotherapy Targeting PD-1 or PD-L1 in Cancer
    Huang, Haozhe
    BIOINFORMATICS AND BIOMEDICAL ENGINEERING, PT II, IWBBIO 2024, 2024, 14849 : 55 - 69
  • [2] PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
    Liu, Jinhua
    Chen, Zichao
    Li, Yaqun
    Zhao, Wenjie
    Wu, JiBiao
    Zhang, Zhen
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [3] Progress on biphenyl derivatives as PD-1/PD-L1 inhibitors
    Wang, Shurong
    Wang, Yuli
    Yan, Hong
    MEDICINAL CHEMISTRY RESEARCH, 2023, 32 (10) : 2089 - 2115
  • [4] Reducing PD-L1 Expression by Degraders and Downregulators as a Novel Strategy to Target the PD-1/PD-L1 Pathway
    Wang, Zhijie
    Yuan, Lin
    Liao, Xiaotong
    Guo, Xia
    Chen, Jianjun
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (08) : 6027 - 6043
  • [5] Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure
    Pathak, Ranjan
    Pharaon, Rebecca R.
    Mohanty, Atish
    Villaflor, Victoria M.
    Salgia, Ravi
    Massarelli, Erminia
    CANCERS, 2020, 12 (12) : 1 - 13
  • [6] PD-L1 Amino Acid Position 88 Represents a Hotspot for PD-L1 Stability With Relevance for PD-L1 Inhibition
    Claass, Luise Victoria
    Schultheiss, Christoph
    Scholz, Rebekka
    Paschold, Lisa
    Simnica, Donjete
    Heinemann, Volker
    Stintzing, Sebastian
    Binder, Mascha
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [7] Molecular dynamics simulations elucidate conformational selection and induced fit mechanisms in the binding of PD-1 and PD-L1
    Liu, Wenping
    Huang, Bing
    Kuang, Yashu
    Liu, Guangjian
    MOLECULAR BIOSYSTEMS, 2017, 13 (05) : 892 - 900
  • [8] Immune checkpoint inhibitors targeting PD-1/PD-L1 in the treatment of human lymphomas
    Ribatti, Domenico
    Cazzato, Gerardo
    Tamma, Roberto
    Annese, Tiziana
    Ingravallo, Giuseppe
    Specchia, Giorgina
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [9] The role of the PD-1/PD-L1 axis in macrophage differentiation and function during pregnancy
    Zhang, Yonghong
    Ma, Lina
    Hu, Xiaohui
    Ji, Jinlu
    Mor, Gil
    Liao, Aihua
    HUMAN REPRODUCTION, 2019, 34 (01) : 25 - 36
  • [10] Do the benefits of being a smoker hint at the existence of PD-1/PD-L1 sensitizers for patients on single-agent immunotherapy?
    Zaleskis, Gintaras
    Pasukoniene, Vita
    Characiejus, Dainius
    Urbonas, Vincas
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (08)
12345